SCHEMBL7925119

SCHEMBL7925119

CC(CCC=O)Cc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 5/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
SIGMAR1 Q99720 4/20 0.45
SLC6A2 P23975 2/20 0.45
MAOA P21397 1/20 0.45
SLC6A4 P31645 1/20 0.45
SLC6A3 Q01959 1/20 0.45
CYP2A6 P11509 1/20 0.45
ADORA2A P29274 1/20 0.45
ADORA1 P30542 1/20 0.45
EPHX1 P07099 1/20 0.44
SLC18A2 Q05940 1/20 0.42
CYP2D6 P10635 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
TRPA1 O75762 1/20 0.41
TDP1 Q9NUW8 1/20 0.40
ADH1B P00325 1/20 0.39
ADH1C P00326 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7864722 0.89 TAAR1 (0.47) TAAR1MEN1KMT2ASIGMAR1SLC6A2
SCHEMBL17120347 0.83 TRPA1 (0.53) TAAR1MEN1KMT2ASIGMAR1SLC6A2
SCHEMBL15865878 0.81 ITGB1 (0.36) TAAR1MEN1KMT2ANPC1RAB9A
SCHEMBL25209356 0.80 TAAR1 (0.53) TAAR1MEN1KMT2ASIGMAR1SLC6A2
SCHEMBL7354997 0.80 TAAR1 (0.53) TAAR1MEN1KMT2ASIGMAR1SLC6A2
SCHEMBL25045960 0.79 SIGMAR1 (0.44) TAAR1MEN1KMT2ASIGMAR1SLC6A2
SCHEMBL27694653 0.79 CA1 (0.47) TAAR1MEN1KMT2A
SCHEMBL17636071 0.78 TAAR1 (0.44) TAAR1MEN1KMT2ASIGMAR1SLC6A2
SCHEMBL4607534 0.78 ALDH1A1 (0.43) TAAR1MEN1KMT2ANPC1RAB9A
SCHEMBL8742456 0.77 EPHX1 (0.59) TAAR1SIGMAR1SLC6A2MAOASLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4516118-A2 USE OF AMBOCENIDE® FOR REINFORCING A LILY OF THE VALLEY NOTE Symrise AG (DE) 2025-03-05 EP claimed
US-20200239810-A1 USE OF AMBROCENIDE ® FOR INTENSIFYING A LILY OF THE VALLEY SCENT SYMRISE AG (DE) 2020-07-30 US claimed
EP-3883927-B1 AMBER ODORANT FIRMENICH & CIE (CH) 2025-10-01 EP disclosed
EP-4516118-A2 USE OF AMBOCENIDE® FOR REINFORCING A LILY OF THE VALLEY NOTE Symrise AG (DE) 2025-03-05 EP disclosed
US-12139469-B2 Amber odorant FIRMENICH SA (CH) 2024-11-12 US disclosed
US-20220106285-A1 AMBER ODORANT FIRMENICH SA (CH) 2022-04-07 US disclosed
EP-3883927-A1 AMBER ODORANT Firmenich SA (CH) 2021-09-29 EP disclosed
CN-113423700-A Amber flavor agent 弗门尼舍有限公司 2021-09-21 CN disclosed
US-11091723-B2 Use of ambrocenide® for intensifying a lily of the valley scent SYMRISE AG (DE) 2021-08-17 US disclosed
EP-3668850-B1 AMBER ODORANT FIRMENICH & CIE (CH) 2021-07-14 EP disclosed
US-10889558-B2 Amber odorant FIRMENICH SA (CH) 2021-01-12 US disclosed
WO-2020239682-A1 AMBER ODORANT FIRMENICH SA (CH) 2020-12-03 WO disclosed
US-20200299254-A1 AMBER ODORANT FIRMENICH SA (CH) 2020-09-24 US disclosed
US-20200239810-A1 USE OF AMBROCENIDE ® FOR INTENSIFYING A LILY OF THE VALLEY SCENT SYMRISE AG (DE) 2020-07-30 US disclosed
EP-3665163-A1 USE OF AMBROCENIDE ® FOR INTENSIFYING A LILY OF THE VALLEY SCENT Symrise AG (DE) 2020-06-17 EP disclosed
US-6310033-B1 2,4-DIMETHYL-5-PHENYLPENTANAL; PERFUMES BUSH BOAKE ALLEN INC. 2001-10-30 US disclosed
US-5162318-A Which have pulmonary surfactant secretion promoting activity YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1992-11-10 US disclosed
EP-0454330-A1 Benzimidazolinone derivatives YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1991-10-30 EP disclosed
US-4987132-A PLATELET ACTIVATING FACTOR ANTAGONISTS YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 1991-01-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10889558-B2 Amber odorant TRPA1, TAS2R41, OPRM1 TAAR1 375/4885MEN1 739/4885KMT2A 3225/4885
US-20220106285-A1 AMBER ODORANT OPRM1, TRPA1, PYM1 TAAR1 272/4885MEN1 855/4885KMT2A 4117/4885
US-20200239810-A1 USE OF AMBROCENIDE ® FOR INTENSIFYING A LILY OF THE VALLEY SCENT OR51E2, OR10J3, ALG3 TAAR1 46/4885MEN1 2519/4885KMT2A 3340/4885
US-11091723-B2 Use of ambrocenide® for intensifying a lily of the valley scent OR51E2, OR10J3, TRPA1 TAAR1 55/4885MEN1 2541/4885KMT2A 3241/4885
US-20200299254-A1 AMBER ODORANT TRPA1, TAS2R41, OPRM1 TAAR1 375/4885MEN1 739/4885KMT2A 3225/4885
US-12139469-B2 Amber odorant OPRM1, TRPA1, PYM1 TAAR1 272/4885MEN1 855/4885KMT2A 4117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.